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1Endothelial cells (ECs) line the inner wall of all blood ves-sels and are critical in maintaining the barrier function of 
the vasculature. Under inflammatory conditions, penetration 
of ECs by macromolecules and immune cells can be achieved 
via both transcellular mechanisms—possibly involving intra-
cellular structures, such as vesiculo-vacuolar organelles)—and 
paracellular mechanisms—involving breaching of tightly con-
nected junctions between adjacent ECs.1–3 With respect to the 
latter, it is now well accepted that strict regulation of expres-
sion, distribution, and function of EC junctional proteins is piv-
otal for maintaining steady-state stability, integrity, and barrier 
properties of vessel walls. Furthermore, in response to injury or 
infection, controlled opening/loosening of EC junctions plays a 
critical role in supporting an effective inflammatory response. 
This occurs through increased vascular permeability to macro-
molecules, facilitating leakage of essential blood-borne immu-
noregulatory and proinflammatory proteins to the extravascular 
tissue (eg, immunoglobulins and components of the comple-
ment cascade) and also enabling breaching of venular walls 
by transmigrating immune cells.1–3 Because of their essential 
role in such biological functions, there is immense interest in 
the signaling properties of EC junctional molecules under both 
physiological and pathological conditions.1–3 In addition, there 
is increasing awareness and, indeed, evidence for altered cell 
surface expression of EC junctional molecules in inflamma-
tion, phenomena that are currently under investigation in terms 
of their associated mechanisms and biological implications. 
This review summarizes the key findings related to this topic.
Expression and Function of EC  
Junctional Molecules
The single-cell EC layer of blood vessels is held together via 
complex structures comprising numerous transmembrane 
proteins that interact both with binding ligands on adjacent 
cells and with associated intracellular partners.1–4 Two key 
junctional structures are tight junctions that incorporate 
members of the junctional adhesion molecule (JAM) family, 
EC-selective adhesion molecule, and claudins and adherens 
junctions that include VE-Cadherin.1–5 Numerous other adhe-
sion molecules are also present at EC contacts, such as plate-
let endothelial cell adhesion molecule-1 (PECAM-1), CD99, 
CD47, activated leukocyte cell adhesion molecule-1, and 
ICAM-2, molecules that contribute to junction formation and 
properties1–6 (Figure). A growing body of evidence also indi-
cates the expression of EC junctional molecules in a variety 
of EC intracellular compartments, such as the membranous 
lateral border recycling compartment (LBRC), endosomes, 
and vesicle-type structures (Figure). Recent developments 
strongly support the concept that intracellular stores of EC 
junctional molecules contribute to maintaining the integrity 
and function of the endothelium (discussed later).4
The 2 key principal roles of EC junctions during inflamma-
tion are regulation of leukocyte migration out of the vascular 
lumen and regulation of vascular permeability to macromol-
ecules. With respect to the former, ECs are critical in attract-
ing and facilitating the transmigration of immune cells, both 
for tissue surveillance and in direct response to sterile and 
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Abstract—Endothelial cells line the lumen of all blood vessels and play a critical role in maintaining the barrier function 
of the vasculature. Sealing of the vessel wall between adjacent endothelial cells is facilitated by interactions involving 
junctionally expressed transmembrane proteins, including tight junctional molecules, such as members of the junctional 
adhesion molecule family, components of adherence junctions, such as VE-Cadherin, and other molecules, such as platelet 
endothelial cell adhesion molecule. Of importance, a growing body of evidence indicates that the expression of these 
molecules is regulated in a spatiotemporal manner during inflammation: responses that have significant implications for 
the barrier function of blood vessels against blood-borne macromolecules and transmigrating leukocytes. This review 
summarizes key aspects of our current understanding of the dynamics and mechanisms that regulate the expression 
of endothelial cells junctional molecules during inflammation and discusses the associated functional implications 
of such events in acute and chronic scenarios.  (Arterioscler Thromb Vasc Biol. 2016;36:00-00. DOI: 10.1161/
ATVBAHA.116.307610.)
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infectious insults. Specifically, at sites of inflammation, leu-
kocytes exhibit several luminal interactions with ECs, initi-
ating with leukocyte rolling along the endothelium, followed 
by leukocyte arrest and crawling. These events are mediated 
by a cascade of intricate molecular and cellular interactions 
between immune cells and ECs as described by the leuko-
cyte adhesion cascade.7 During leukocyte crawling, leuko-
cytes engage with EC junctions and begin breaching venular 
walls.2,6,7 Migration through the EC barrier (transendothelial 
cell migration; TEM) can occur via both transcellular and 
paracellular modes. Although significant use of the transcellu-
lar route has been reported across the blood–brain and blood–
retinal barriers during inflammatory pathologies,8 paracellular 
diapedesis seems to be the most prevalent mode of breach-
ing ECs both in vitro and in vivo (≈70% to 90%).3,6 This was 
directly demonstrated in vivo through the application of high-
resolution 3-dimensional intravital imaging of inflamed mouse 
cremaster muscle venules where paracellular TEM was found 
to account for ≈90% of all observed neutrophil TEM events 
as induced by multiple inflammatory stimuli.9 Furthermore, 
Figure. Mechanisms associated with regulation of expression of key endothelial cell junctional adhesion molecules. Constitutive junc-
tional adhesion molecule regulation involves protein internalization in endosomes and vesicular structures, their recycling back to the cell 
surface, and degradation (eg, via lysosomes). Certain proteins, such as PECAM-1, JAM-A, and CD99, can also cycle between the cell 
membrane and the LBRC under basal conditions. Under inflammatory conditions, the expression of adhesion molecules at endothelial 
cell junctions is regulated through additional mechanisms. Namely, increased gene transcription and mRNA translation leading to upregu-
lation of total junctional molecule expression at protein level in endothelial cells. JAM-A, JAM-C, and PECAM-1 can be redistributed away 
from cell junctions to nonjunctional membranes, whereas internalization from the plasma membrane of certain molecules, such as VE-
Cadherin, is increased. Cycling of the LBRC increases during inflammation, allowing the recruitment of additional PECAM-1 and CD99 
molecules to junctional sites. Enzymatic cleavage and shedding from the cell surface reduces the expression of junctional adhesion mole-
cules at endothelial cell junctions. The mechanisms illustrated in the diagram can regulate inflammatory responses, such as vascular leak-
age, and the magnitude and profile of leukocyte transendothelial cell migration (TEM). For example, with respect to the latter, NE cleavage 
of JAM-C is known to promote neutrophil rTEM. ER indicates endoplasmic reticulum; ESAM, endothelial cell-selective adhesion molecule; 
JAM, junctional adhesion molecule; LBRC, lateral border recycling compartment; NE, neutrophil elastase; PECAM, platelet endothelial cell 
adhesion molecule; and rTEM, reverse transendothelial cell migration.
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a mouse strain in which the EC junctions were stabilized 
through expression of a VE-Cadherin-α-catenin fusion com-
plex (replacing endogenous VE-Cadherin) exhibited reduced 
leukocyte (neutrophil and lymphocyte) infiltration in several 
models of inflammation, providing strong supportive evidence 
for the involvement of EC junctions in leukocyte trafficking.10 
Paracellular leukocyte TEM is mediated by an elaborate series 
of interactions between leukocytes and EC JAMs, including 
PECAM-1, JAMs, CD47, activated leukocyte cell adhesion 
molecule-1, EC-selective adhesion molecule, ICAM-2, and 
CD99 (for reviews on this topic, see references Nourshargh et 
al,2 Vestweber,3 Muller,4 Nourshargh and Alon,6 and Gerhardt 
and Ley11), and there exists some evidence to suggest that EC 
junctional molecules can also support leukocyte transcellular 
TEM.4,6 In addition, there is strong evidence to indicate distinct 
and sequential roles for these molecules in different stages of 
leukocyte movement through venular walls.2,4,6 However, care 
needs to be exercised in formulating general concepts because 
roles of different molecules in different stages of leukocyte 
transmigration seem to be governed to a large extent by the 
nature of the inflammatory reaction being studied (eg, the tis-
sue and genetic background of animals in which it is elicited) 
and the leukocyte subtype under observation.3,4,6,7,11 In addi-
tion, EC phenotype, morphology, and junctional composition 
can vary between different vascular beds, differences that may 
well impact the profile and dynamics of vascular permeability 
and leukocyte–EC interactions.12
Vascular permeability to plasma proteins, and the subse-
quent formation of tissue edema, is another important pro-
tective physiological reaction to tissue injury. Although it is 
well established that neutrophils can mediate vascular perme-
ability13 and numerous neutrophil-derived factors have been 
implicated in this response,13,14 the precise molecular basis of 
this reaction remains unclear. Of importance, recent develop-
ments in this area have provided compelling evidence for the 
existence of distinct molecular pathways in induction of vas-
cular permeability and leukocyte TEM.1,15,16 Specifically, the 
works of Vestweber and colleagues have shed new insights 
into the mechanism through which VE-Cadherin can mediate 
these responses.3,10,16–18 Briefly, through generation of knock-
in mice in which specific tyrosine residues of VE-Cadherin 
were mutated to phenylalanine, evidence was obtained for the 
phosphorylation state of VE-Cadherin in maintaining func-
tional EC junctions.16 Importantly, this study showed that 
the phosphorylation status of 2 distinct tyrosine residues of 
VE-Cadherin can selectively and exclusively regulate either 
vascular permeability or leukocyte diapedesis.16
Other junctional molecules involved in the regulation of 
vascular permeability include JAM-A and JAM-C. Despite the 
high percentage of homology between the 2 proteins, these 
molecules seem to have opposing roles in regulating barrier 
function of ECs. For example, although genetic deletion and 
blockade of JAM-A generally results in increased EC perme-
ability,19 knocking down JAM-C decreases EC permeability 
in vitro.20 Of note, as opposed to cultured macrovascular ECs 
(eg, human umbilical vein ECs) that constitutively express 
JAM-C at cell–cell contacts, quiescent microvascular ECs 
in culture express JAM-C predominantly within intracel-
lular stores that can be mobilized to junctions after cellular 
stimulation. The latter seems to provide a mechanism through 
which EC permeability is regulated.20 However, the role of 
EC JAM-C in vascular permeability in vivo remains unclear 
and may depend on the nature of the inflammatory model. 
Although treatment of wild-type mice with soluble recombi-
nant JAM-C (used as a competitive blocker of JAM-C interac-
tions) reduces vascular permeability in response to histamine 
or VEGF,20 specific antibody blockade of endothelial JAM-C 
leads to increased vascular leakage in a model of cutaneous 
infection by Leishmania major.21 Of note, genetic inactivation 
of the related tight junction–associated protein EC-selective 
adhesion molecule attenuates the induction of vascular perme-
ability and delays leukocyte diapedesis in vivo.22
Collectively, because there is undisputed evidence for 
the involvement of EC junctional molecules in regulation 
of endothelial barrier function both at rest and during tissue 
injury, better understanding of the mechanisms that regulate 
remodeling of EC junctions, and the associated biological 
impact, could shed light on the intricacies of many vascular 
and inflammatory processes.
Mechanisms Regulating the Surface Expression 
of EC Junctional Molecules in Inflammation
Several studies have reported on altered expression of EC 
junctional molecules in vitro and in vivo, with some studies 
associating such changes with altered functional readouts.1,4 
At present, investigations into regulation of EC junctional 
molecule expression are at an early stage, but to date, several 
diverse mechanisms have been suggested as discussed later 
(see also Tables 1 and 2).
Internalization and Redistribution
Internalization and redistribution of molecules to intracellular 
compartments are commonly reported means through which 
the expressions of a wide range of cell surface–presented 
transmembrane proteins are regulated in many cell types. 
Such responses are also emerging as important mechanisms 
in control of EC barrier functions. Several EC junctional 
proteins, such as PECAM and VE-Cadherin, undergo some 
form of intracellular recycling or degradation.3,4 In addition, 
many others, such as JAM-C, JAM-A, and CD99, are also 
present in intracellular stores and are, therefore, susceptible 
to mobilization to and from EC junctions post stimulation 
(Figure).4 In this context, ECs show a unique array of intracel-
lular compartments that are associated with junctional mol-
ecule internalization, storage, and recycling. These include 
the membrane invagination structure termed LBRC (com-
monly found in close proximity of EC junctional lateral bor-
ders), components of the vesicular system, vesiculo-vacuolar 
organelles and caveolae, and endosomes that are additionally 
associated with delivery of proteins to lysosomes for destruc-
tion. Current evidence suggests that the nature of the carrier 
system is relatively specific to the cargo molecule, with some 
molecules showing intracellular recycling both at rest and also 
during acute inflammation, as discussed later.
The LBRC represents an internalization organelle, appar-
ently unique to ECs and containing key junctional molecules, 
including PECAM-1, JAM-A, CD99, and the poliovirus 
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Table 1. Key Reported Changes in Expression of EC Junctional Molecules Post Inflammation, Excluding Cleavage-Induced 
Changes (Listed in Table 2)
Molecule Inflammatory Stimuli/Model Change in Expression Proposed Mechanism Functional Implications References
In vitro
  PECAM-1 TNF+IFNγ (HUVECs) ↓ mRNA mRNA destabilization ↓ leukocyte TEM Ozaki et al23, Rival et 
al24, Shaw et al25, and 
Stewart et al26
↓ total and junctional 
expression
Protein internalization and 
degradation
No effect on leukocyte 
TEM
Redistribution to the cell surface
  VE-Cadherin TNF (HUVECs/primary 
lung EC)
↓ junctional expression Tyrosine phosphorylation ↑ permeability Wessel et al16, Alcaide 
et al27, Allport et al28, 
Shaw et al29
Gap formation curtain 
effect
Facilitate neutrophil TEM
VEGF ↑ internalization Endocytosis through a VEGFR-2-
Src-Vav2-Rac-PAK signaling axis
↑ permeability Gavard and Gutkind30
TNF (primary lung EC) ↓ junctional expression Leukocyte induced 
SHP2-mediated Y731 
dephosphorylation and 
endocytosis through AP-2
↑ leukocyte TEM Wessel et al16
  JAM-A bFGF Redistribution to cell 
membrane
Dissociation from integrin αvβ3 ↑ angiogenesis Naik et al
31
OxLDL (human and mouse 
aortic ECs)
Redistribution to apical 
membrane
Statin-dependent ↑ monocyte adhesion 
and TEM
Schmitt et al32
  JAM-C OxLDL ↑ total protein expression None described ↑ monocyte adhesion 
and TEM
Keiper et al33
↑ expression at 
nonjunctional sites
Thrombin Relocalization to junctions None described Binding and modulation 
of β3 integrin activity
Li et al34
↑ permeability
VEGF, Histamine Relocalization to junctions None described Regulates actomyosin 
contractility
Orlova et al20
Stabilization of  
VE-Cadherin
↑ permeability
In vivo
  JAM-A Murine model of 
atherosclerosis
↑ mRNA and protein 
in arterial ECs and 
atherosclerotic plaques
Disturbed flow and upregulation 
of miR-145
↑ monocyte recruitment 
into the arterial wall
Ostermann et al35, 
Babinska et al36, 
Schmitt et al37
Luminal redistribution
Murine model of hepatic 
I-R injury
Protein upregulation None described Supports neutrophil TEM Khandoga et al38
  JAM-C Murine model of 
atherosclerosis
↑ protein in atherosclerotic 
plaques
None described None described Keiper et al33
Human rheumatoid arthritis 
and osteoarthritis
↑ protein in synovial tissue None described None described Rabquer et al39
Murine cremaster muscle 
I-R injury
↓ junctional expression ROS-mediated loss of JAM-C Polarized neutrophil TEM Woodfin et al9, 
Scheiermann et al40, 
Colom et al41
Redistribution to 
nonjunctional membrane
Regulation of systemic 
inflammation
Mice injected IV with anti-
JAM-C mAb
Redistribution to 
nonjunctional membrane
Loss of JAM-C/JAM-B 
interaction
↑ monocyte adhesion to 
lymph nodes
Lamagna et al42
bFGF indicates basic fibroblast growth factor; EC, endothelial cell; HUVECs, human umbilical vein endothelial cells; IFNγ, interferon-γ; I-R, ischemia–reperfusion; 
IV, intravenously; JAM, junctional adhesion molecule; mAb, monoclonal antibody; OxLDL, oxidized low-density lipoprotein; PECAM, platelet endothelial cell adhesion 
molecule; TEM, transendothelial cell migration; and TNF, tumor necrosis factor.
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receptor (CD155), but not VE-Cadherin, which is actively 
excluded from this domain.4,50,51 This compartment is believed 
to provide a means through which adhesion molecules and 
additional membrane can be efficiently recruited to sites of 
leukocyte diapedesis on demand.4 In support of this concept, 
changes in the intracellular pool of PECAM-1 have been 
located to sites where the LBRC is redirected toward the cell 
border to support paracellular migration52 or toward the cell 
body during transcellular migration.53 Although there is now 
ample evidence to support a role for LBRC in regulation of 
leukocyte TEM, there remain many unanswered questions 
regarding the trafficking of this structure, an area that has been 
developed in recent studies by Muller et al.4 For example, ves-
icles of the LBRC compartment are moved by kinesin molec-
ular motors along microtubules.4,50,52 Furthermore, although it 
has been known for >20 years that a transient increase in EC 
cytosolic-free calcium is required for TEM, Weber et al54 have 
recently demonstrated that the Ca2+ channel, transient recep-
tor potential canonical 6 (TRPC6), mediates this response and 
have linked this reaction with LBRC trafficking. Specifically, 
homophilic interaction of leukocyte and EC PECAM trig-
gered the activation of TRPC6 and promoted its colocalization 
with PECAM-1 during TEM and trafficking of the LBRC. Of 
note, selective inactivation of EC TRPC6 blocked neutrophil 
TEM while its activation rescued TEM during conditions of 
PECAM blockade, suggesting that TRPC6 acts downstream 
of PECAM-1 ligation. The importance of this pathway in reg-
ulation of leukocyte transmigration was also demonstrated in 
vivo, where chimeric mice deficient in EC TRPC6 exhibited 
defective neutrophil TEM in a model of acute inflammation.54 
Downstream of the pathway triggered by PECAM engage-
ment, trafficking of the LBRC is also regulated by EC CD99 
through activation of PKA, a mechanism involving ezrin and 
soluble adenylyl cyclase.55 Collectively, such studies have 
shed much light on the mechanism through which LBRC is 
recruited to sites of leukocyte TEM and have strengthened 
the evidence for the functional importance of this trafficking 
toward and away from EC junctions.4
Changes in VE-Cadherin junctional expression can also 
have profound impact on EC barrier function.5 VE-Cadherin 
displays constitutive endosomal internalization from the EC 
surface via a clathrin-dependent pathway56 and can then be 
lysosomally degraded46 or recycled back to the EC surface 
through Rab11a-mediated trafficking to recover EC barrier 
properties after junctional challenge.57 VE-Cadherin mainte-
nance at EC junctions is regulated by different cytoplasmic 
binding partners of this molecule, such as p120-catenin and 
Src kinase. Briefly, p120 dissociation from VE-Cadherin 
intracellular tail regulates cadherin levels, preventing its 
endocytosis and degradation.46,56 In addition, more recent 
works identified a specific motif of VE-Cadherin intracel-
lular tail that is required for p120 binding and VE-Cadherin 
internalization. Mutations in this region strongly affect EC 
migration, although the impact of such effects on EC barrier 
function remains to be elucidated.58 On the contrary, changes 
in VE-Cadherin phosphorylation status destabilize EC con-
tacts, a response that supports vascular leakage and leukocyte 
migration.3,5,16,27,59 VE-Cadherin phosphorylation can be regu-
lated by p12027 and the kinases Src and Pyk2 in response to 
ICAM-1 ligation.59 This is necessary for leukocyte TEM but 
does not imply internalization of the molecule and so will not 
be discussed further. Phosphorylation of residues Y658 and 
Y685 have, however, been shown to be responsible for inter-
nalization and ubiquitinization of the protein after bradykinin 
Table 2. Cleavage of EC Junctional Molecules During Inflammation
Molecule Model Mechanism Functional Implications References
PECAM-1 Serum starvation (HUVECs, EOMA, 
BAECs)
Cleavage by caspases and shedding by 
MMPs
None described Ilan et al43
VE-Cadherin fMLP stimulated neutrophils 
(HUVECs)
Cleavage by neutrophil elastase and 
cathepsin G
↑ permeability Hermant et al44
Support neutrophil TEM
Thrombin stimulation (HUVECs) Cleavage by ADAM-10 ↑ permeability Schulz et al45
Support T-cell migration
TNF stimulation (HUVECs) Cleavage-dependent on tyrosine kinases, 
Src kinase, and MMPs
None described Xiao et al46
JAM-A PMA, TNFα+ IFNγ, PAF (HUVECs) Cleavage by ADAM-10, ADAM-17 ↓ EC migration Koenen et al47
↓ neutrophil TEM
JAM-B HBMEC incubation with tumor 
cell–secreted supernatant
Cleavage by cathepsin S ↑ TEM of brain metastatic 
tumor cells
Sevenich et al48
JAM-C LPS, IL1-β, IL-18, MIF, IL-17, TNF, 
PMA (HUVECs)
Cleavage by ADAM-10, ADAM-17 Supports angiogenesis Rabquer et al49, Colom 
et al41
Murine cremaster muscle I-R and 
local LTB4
Cleavage by NE as supported by 
presentation of NE to JAM-C via neutrophil 
Mac-1
↑ neutrophil rTEM
BAECs indicates bovine aortic endothelial cells; bFGF, basic fibroblast growth factor; EOMA, mouse hemangioendothelioma endothelial cells; HBMEC, human 
brain microvascular endothelial cells; HUVECs, human umbilical vein endothelial cells; IFNγ, interferon-γ; IL, interleukin; JAM, junctional adhesion molecule; NE, 
neutrophil elastase; OxLDL, oxidized low-density lipoprotein, PECAM, platelet endothelial cell adhesion molecule; TEM, transendothelial cell migration; and TNF, 
tumor necrosis factor.
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and histamine-induced permeability.60 This phenomenon 
occurs specifically in veins and not arteries, possibly because 
of the shear stress–dependent activation of junctional Src in 
the former, and regulates loosening of venular EC junctions 
and leakage.60 More recently, heterotrimeric G protein Gα13 
binding to VE-Cadherin has been shown to regulate Src-
mediated phosphorylation of VE-Cadherin and its internal-
ization, identifying a unique role for Gα13 in mediating EC 
barrier disruption in vivo in response to vascular permeability 
factors, such as histamine and bradykinin.61 Internalization 
of the molecule can also be regulated by phosphorylation of 
S665 through the VEGFR-2–Src–Vav2–Rac–PAK signaling 
axis after VEGF stimulation.30 This promotes VE-Cadherin 
association with β-arrestin2 and its internalization through 
clathrin-coated vesicles.
As well as responding to inflammatory mediators, 
VE-Cadherin is also transiently displaced from EC junc-
tions by transmigrating leukocytes, a reaction described as 
the curtain effect because it rapidly reseals behind emigrat-
ing cells.28,29 In addition, VE-Cadherin can be internalized 
in response to leukocyte–EC interactions.16 New findings 
have identified the molecular basis of this phenomenon by 
demonstrating how leukocyte–EC interactions trigger SHP2-
mediated dephosphorylation of Y731 and further endocytosis 
of VE-Cadherin through binding of adaptin AP-2.16 Although 
Y731 dephosphorylation seemed essential for leukocyte 
TEM in vivo, it was not necessary for inflammation-induced 
vascular permeability. Conversely, phosphorylation of Y685 
was required for junction destabilization but was dispens-
able for leukocyte diapedesis, indicating the intricacies of 
regulating VE-Cadherin phosphorylation and its functional 
implications.16 Under resting conditions, VE-Cadherin binds 
to VE-PTP, a phosphatase that maintains VE-Cadherin and 
its associated catenins in a nonphosphorylated state criti-
cal for optimal adhesive functions of VE-Cadherin and EC 
contact integrity. After engagement of leukocytes with 
ECs or stimulation with VEGF, VE-PTP dissociates from 
VE-Cadherin, promoting its phosphorylation, subsequent 
loss of VE-Cadherin interactions, and hence, loosening of EC 
junctions.18 Of note, VE-PTP has also recently been described 
to regulate EC junctional stability by a VE-Cadherin-
independent mechanism involving its interaction with Tie-2. 
Briefly, VE-PTP–Tie 2 interaction can dampen the tyrosine 
kinase activity of this receptor and, hence, its ability to sta-
bilize EC junctions. Pharmacological or genetic ablation of 
VE-PTP leads to increased EC junctional stability in vivo via 
Tie-2, counteracting vascular leakage and leukocyte transmi-
gration induced by inflammatory mediators. Thus, activation 
of Tie-2 via inhibition of VE-PTP protects endothelial junc-
tions against inflammation-induced destabilization and over-
rides the negative effect of VE-PTP inhibition on the adhesive 
function of VE-cadherin.62 VE-Cadherin association with one 
or another partner is reversible and can be spatially and tem-
porally regulated. Of note, the actin-binding protein EPS8 has 
recently been identified as a binding partner of VE-Cadherin. 
EPS8 promotes VE-Cadherin ubiquitination and phosphory-
lation, leading to increased internalization and enhanced cell 
surface turnover of the molecule.63 This interaction medi-
ates transduction of signals impinging on the regulation of 
the transcriptional cofactor Yes-associated protein and, as a 
result, modulates vascular permeability.63
Similar to internalization, redistribution of adhesion 
molecules away from EC junctions and onto the cell body 
may represent a means through which an inflammatory reac-
tion is regulated. Such a response may facilitate the devel-
opment of an inflammatory event through promotion of 
leukocyte adhesion to the EC surface (via increased expres-
sion of adhesion molecules on the EC apical membrane) or 
its termination through inhibiting TEM (via reduced expres-
sion of molecules at junctions between adjacent cells). 
Redistribution of EC junctional molecules has been reported 
within in vitro and in vivo models of acute inflammation 
with respect to several proteins (Figure and Table 1). For 
example, expressions of PECAM-1 and JAM-A are reduced 
from junctions of human umbilical vein ECs treated with the 
cytokine combination interferon-γ and tumor necrosis fac-
tor, with no apparent reduction in total cellular protein lev-
els.23,64 A similar phenomenon was noted for JAM-A in brain 
ECs stimulated with CCL2 and LPS, a response that was 
associated with increased adhesion of monocytes and neu-
trophils.65 This occurred via internalization of the molecule 
by macropinocytosis and its transient storage in recycling 
endosomes before being recruited back to the apical side of 
ECs. These findings indicate that redistribution may be sup-
ported by internalization pathways. JAM-A redistribution to 
the apical membrane of aortic ECs also occurs in response to 
proatherogenic oxidized lipoproteins in vitro32,65 and in vivo 
in murine models of atherosclerosis in regions of disturbed 
flow.37 The latter response was associated with increased 
monocyte recruitment into the arterial wall and enhanced 
atherosclerotic lesion formation.37
A significant body of work has investigated the regulation 
of expression of JAM-C and its functional implications. In 
vitro, human umbilical vein ECs treated with oxidized low-
density lipoprotein, but not tumor necrosis factor, interleukin-
1β, VEGF, or histamine, showed redistribution of JAM-C from 
junctions to the cell surface.20,33 This redistribution resulted in 
the ability of JAM-C to mediate both leukocyte adhesion and 
TEM as compared with JAM-C on unstimulated ECs that only 
supported leukocyte diapedesis.20,33 As previously mentioned, 
in quiescent microvascular ECs, JAM-C is mainly intracellu-
larly expressed and is recruited to junctions after short-term 
stimulation with stimuli, such as VEGF or histamine. This 
induced expression of JAM-C at EC junctions was shown to 
support vascular permeability, a response mediated through 
modulation of actomyosin-based endothelial contractility 
and regulation of VE-Cadherin–mediated cell–cell contacts 
in a Rap1-dependent manner.20 In contrast to in vitro stud-
ies, in vivo JAM-C is expressed at EC junctions, as indicated 
through analysis of numerous murine tissues.40 However, in 
line with in vitro works, there is evidence for the presence 
of JAM-C in intracellular vesicles within microvascular ECs 
in vivo.40 This intracellular store of JAM-C appeared to be 
available for mobilization under inflammatory conditions, in 
that redistribution of JAM-C from intracellular vesicles and 
EC junctions to EC nonjunctional plasma membrane regions 
was noted in a murine model of ischemia–reperfusion injury. 
The in vivo redistribution of EC JAM-C was associated with 
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enhanced luminal neutrophil–venular wall interactions.9,40 As 
well as mediating leukocyte adhesion and diapedesis, there 
is also evidence from both in vitro and in vivo works for the 
ability of EC JAM-C to mediate polarized migration of leu-
kocytes through EC monolayers.9,66 Specifically, Bradfield et 
al66 showed that inhibition of EC JAM-C can lead to enhanced 
monocyte reverse TEM (rTEM) through tumor necrosis fac-
tor–stimulated human umbilical vein ECs, that is, increased 
frequency of monocyte movement in an abluminal-to-luminal 
direction. In vivo, our studies provided the first direct evi-
dence for the occurrence of neutrophil rTEM in a mammalian 
model (inflamed mouse cremaster muscle), a phenomenon 
that was significantly enhanced under conditions of reduced 
EC junctional expression or functionality of JAM-C. This 
was achieved through the use of EC JAM-C-deficient mice, 
antibody blockade of JAM-C, or after induction of inflam-
matory reactions, such as ischemia–reperfusion injury, that 
cause reduced expression of junctional EC JAM-C.9,41 The 
underlying mechanism through which EC JAM-C supports 
luminal-to-abluminal TEM is at present unclear but maybe 
related to the role of JAM-C in maintaining EC polarity.67 
Although the pathophysiological relevance of neutrophil 
rTEM requires further investigations, our current data sug-
gest that rTEM neutrophils stemming from a primary site of 
injury may contribute to dissemination of systemic inflamma-
tion and second organ damage.9,41
Overall, it is becoming increasingly clear that altered sur-
face localization and expression of EC junctional molecules, 
as mediated via multiple different modes, can lead to altered 
functional properties of molecules with respect to both leu-
kocyte trafficking and regulation of vascular permeability to 
macromolecules.
Enzymatic Cleavage and Shedding 
From the Cell Surface
Several EC junctional molecules have been reported to be 
enzymatically cleaved by leukocyte and EC-derived proteases. 
Although such events have been implicated to several vascular 
responses, including permeability, immune cell recruitment, 
vascular repair, and angiogenesis (Table 2),68,69 this aspect of 
the field requires further exploration and critical assessment. 
Of importance, caution is required when linking the shed-
ding of a certain cell surface protein to a specific functional 
readout(s) because, commonly, the study cannot rule out the 
possibility that the observed effects was mediated via the 
shedding of other cell surface proteins that were not analyzed. 
Thus, much of the studies cited below are correlations that do 
not necessarily link a defined shedding phenomenon with the 
reported biological observation.
To date, 3 families of proteases have been associated with 
such responses, namely ADAMs, MMPs, and serine prote-
ases. For example, PECAM-1 is shed by MMPs from the cell 
surface during EC apoptosis,43 and VE-Cadherin is reportedly 
cleaved by ADAM10,45 neutrophil elastase (NE), and cathep-
sin G.44 Although the latter studies have associated enzymatic 
cleavage of VE-Cadherin with its role as a regulator of vascu-
lar permeability and leukocyte TEM, additional investigations 
are needed here.
Numerous studies have investigated enzymatic cleavage 
of members of the JAM family. Specifically, JAM-A can be 
cleaved by ADAM17 and, to a lesser extent, by ADAM10 
post stimulation of ECs by certain inflammatory stimuli.47 
Functionally, soluble JAM-A blocked migration of cultured 
ECs and reduced neutrophil TEM in vitro and decreased 
neutrophil infiltration in a murine air pouch model in vivo.47 
Hence, generation of soluble JAM-A, as mediated through 
ADAM17/10, may regulate JAM-A-mediated functions 
through destabilization of JAM-A homophilic interactions 
at sites of inflammation. More recently, Sevenich et al48 
proposed that cathepsin S-mediated cleavage of endothelial 
JAM-B promotes transmigration of metastatic cells across 
brain microvascular ECs. In addition, genetic or pharmaco-
logical targeting of cathepsin B impaired brain metastasis 
in a model of breast cancer, suggesting that proteolytic pro-
cessing of JAM-B at the blood–brain barrier can modulate 
site-specific metastasis,48 although the cleavage of endo-
thelial JAM-B at specific sites of tumor cell TEM was not 
addressed. Findings from our laboratory have demonstrated 
that NE can cleave JAM-C.41 In line with our previous works 
showing that loss of EC JAM-C can promote neutrophil 
rTEM,9 NE cleavage of EC JAM-C promoted neutrophil 
rTEM.41 Under conditions of ischemia–reperfusion injury, 
this response was driven by endogenously generated LTB4, 
and exogenous LTB4 was highly efficacious at causing spe-
cific loss of venular JAM-C without affecting the expression 
of other EC junctional molecules.41 The impact of LTB4-NE 
axis on JAM-C cleavage was totally neutrophil-dependent, 
with NE governing the cleavage of EC JAM-C at sites of 
intense neutrophil infiltration.41 Collectively, our findings 
demonstrated that NE is presented to EC JAM-C via acti-
vated neutrophil Mac-1, and because the latter is a ligand for 
JAM-C,70 Mac-1 seems to act as a molecular bridge between 
NE and JAM-C (Figure). Finally, because the activation of 
local LTB4-NE axis could drive remote organ damage, the 
findings of this study provided additional evidence for the 
involvement of neutrophil rTEM in propagation of a local 
sterile inflammatory response toward a systemic multiorgan 
phenomena.41
After enzymatic cleavage, junctional molecule ectodo-
mains can be shed into the bloodstream. Several such soluble 
forms have been quantified in plasma of patients with inflam-
matory conditions, including trauma, atherosclerosis, and 
rheumatoid arthritis, with the levels commonly correlating 
with the severity of the disease.41,71–74 In our studies, elevated 
concentrations of sJAM-C were detected in plasma of trauma 
patients as compared with healthy controls, a parameter that 
further increased in patients who developed acute respira-
tory distress syndrome post admission.41 Because increased 
plasma content of sJAM-C is associated with trauma-induced 
organ failure41 and is also elevated in serum or synovial fluid 
from rheumatoid arthritis, psoriatic arthritis, osteoarthritis, 
and systemic sclerosis patients,49,75 sJAM-C may be a useful 
vascular-derived biomarker for assessing the extent of a sys-
temic inflammatory response.
Apart from their potential role as biomarkers, relatively 
little is known about the biological consequences of released 
soluble ectodomains in pathophysiological scenarios, and 
T2
AQ15
AQ16
AQ17
Remya Reghu 08/10/16 4 Color Fig: F1 08:32 Art: ATV307610
8  Arterioscler Thromb Vasc Biol  October 2016
there is evidence for both pro- and anti-inflammatory roles. 
Of note, it has been reported that generation of sVE-Cadherin 
contributes to inﬂammation-induced breakdown of endothe-
lial barrier function through inhibition of VE-Cadherin bind-
ing76 and as such promotes leukocyte TEM via increased 
vascular permeability.45 In contrast, exogenous administra-
tion of soluble forms of PECAM-1, JAM-A, and JAM-C 
suppresses leukocyte transmigration in several rodent mod-
els of inflammation.35,40,47,54 The mechanism through which 
these pharmacological interventions act is at present unclear 
but is likely because of competitive binding of the soluble 
molecules with their ligands on either ECs or circulating 
leukocytes.
Impact of Acute Versus Chronic  
Inflammatory Insults on EC Junctional 
Molecule Expression and Function
The mechanisms associated with altered expression of EC 
JAMs (discussed earlier) may differ between acute and chronic 
inflammatory scenarios. Numerous in vitro and in vivo studies 
have investigated the impact of short-term acute inflammatory 
insults on expression of EC regulatory molecules. In such sce-
narios, the expression of molecules on the apical side of ECs 
that facilitate leukocyte adhesion to the endothelium, such as 
E-selectin, P-selectin, ICAM-1, and VCAM-1, is generally 
elevated. This supports increased luminal leukocyte–EC inter-
actions (eg, rolling, crawling, and firm adhesion) and overall 
capture of leukocytes from the blood stream.7,77 Conversely, 
the expression of EC adhesion molecules at cell–cell junc-
tions is commonly reduced under such conditions (Tables 1 
and 2), potentially leading to decreased barrier properties 
of EC junctions. One manner in which this occurs is redis-
tribution of adhesion molecules away from the junctions to 
the luminal side of the venule, a response that may provide a 
means through which leukocytes are guided to EC junctions in 
a haptotactic manner. Although the highly regulated changes 
in junctional molecule expression are necessary for the appro-
priate development of the acute inflammatory response, and 
may indeed play a role in its outcome, evidence suggests that 
they can also have pathogenic implications, as discussed ear-
lier for JAM-C and its role in modulating rTEM and second 
organ damage.
As opposed to acute inflammatory responses, chronic 
inflammatory states allow time for further molecular path-
ways to become activated, such as upregulation of junc-
tional protein expression at transcriptional and translational 
level.33,35,36,39 This can result in increased junctional protein 
expression levels, compared with resting states, as noted, for 
example, in the context of EC JAM-C in atherosclerosis,33 
rheumatoid arthritis, and osteoarthritis39 and EC JAM-A in 
atherosclerotic vessels.35–37 In line with this, increased concen-
trations of soluble junctional molecules have been found in 
plasma from several chronic inflammatory pathologies, such 
as stroke-induced ischemia,73 rheumatoid arthritis,49,72 athero-
sclerosis, and hypertension.71,78 Enhanced expression of EC 
junctional molecules may account for increased or prolonged 
recruitment of leukocytes and their retention during chronic 
inflammation.
Conclusion
The EC barrier allows regulated and selective passage of 
appropriate solutes and immune cells during resting and 
inflammatory conditions. This vital function is mediated 
by interactions between ECs through junctional molecules, 
such as VE-Cadherin, JAMs, and PECAM-1. Remodeling 
of the EC membrane during inflammation includes reor-
ganization of junctional molecules, a response that is piv-
otal for regulation of vascular permeability and leukocyte 
extravasation. Changes in expression levels of junctional 
molecules can also be temporally and spatially regulated by 
inflammatory mediators and leukocyte TEM. These mecha-
nisms include cell surface redistribution and internalization 
of key cell border structures, the recycling of intracellular 
pools of molecules, and their enzymatic cleavage. Such 
changes may also have a role in orchestrating the inflam-
matory response under chronic conditions and affecting its 
resolution. Collectively, better understanding of the molec-
ular mechanisms that mediate the spatiotemporal expression 
and trafficking of EC junctional molecules could identify 
novel means of targeting both acute and chronic inflamma-
tory pathologies.
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